DRKS00013326已完成未知

Clinical study of the influence from the platelet rhich plasma (PRP) application on the therapy of the impingement syndrome (IS) of the shoulder

Otto-von-Guericke-Universität MagdeburgUniversitätsklinik für Orthopädie0 个研究点目标入组 58 人开始时间: 2017年11月17日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Age> 18 years regardless of gender
•- Age <65 LJ
•- Voluntary participation (consent given)
•- IS complaints <2 months
•- No pretreatment
•- Radiological criteria (X-ray / MRI)
•- Bursitis subacromialis / subdeltoidea
•- Tendopathy of RM
•- RM partial rupture type A, B according to Ellmann I-II °
•- Outlet-IS (acromion spur, osteoarthritis of the acromio-clavicular joint)
•Control group: Patients who received a local subacriomal injection of bupivacaine 0.5% due to shoulder IS in the outpatient setting at the Department of Orthopedics, in addition to physiotherapeutic and physical applications. (The data of these patients were collected from 2016 to 2017 retrospectively.)

•Specific shoulder diseases
•- Complete, transmural RM rupture
•- Shoulder instability (habitual, post-official)
•- Omarthrosis
•systemic inflammatory diseases (rheumatoid arthritis, fibromyalgia)
•Indication of disturbed pain processing or psychosomatic underlying illness
•local previous operations
•neurological / muscular diseases
•chronic pain patients
•longer conservative pretreatment (> 6 weeks) and previous local injections
•Age <18 years
•Reference to pension requests
•Pregnant / breastfeeding women
•Contraindications for percutaneous intervention (insufficient coagulation status, etc.)
•existing infectious diseases
•low platelet haematological oncological diseases such as leukemias, myelodysplastic syndromes, malignant lymphomas, anemias
•Patients who are at increased risk for side effects (e.g., in a greatly reduced condition)

发起方

Otto-von-Guericke-Universität MagdeburgUniversitätsklinik für Orthopädie